

Francisco Javier Barrero Hernández

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1672313/publications.pdf>

Version: 2024-02-01

33
papers

2,586
citations

516710

16
h-index

377865

34
g-index

39
all docs

39
docs citations

39
times ranked

4434
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. <i>Lancet Neurology</i> , The, 2019, 18, 1091-1102.	10.2	1,414
2	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , The, 2017, 16, 701-711.	10.2	248
3	Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). <i>Pharmacogenomics Journal</i> , 2005, 5, 135-141.	2.0	106
4	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. <i>JAMA Neurology</i> , 2021, 78, 464.	9.0	95
5	Plasma α -synuclein in patients with Parkinson's disease with and without treatment. <i>Movement Disorders</i> , 2010, 25, 489-493.	3.9	93
6	Short-Term Effects of Manual Therapy on Heart Rate Variability, Mood State, and Pressure Pain Sensitivity in Patients With Chronic Tension-Type Headache: A Pilot Study. <i>Journal of Manipulative and Physiological Therapeutics</i> , 2009, 32, 527-535.	0.9	83
7	Plasma lipid peroxidation in sporadic Parkinson's disease. Role of the l-dopa. <i>Journal of the Neurological Sciences</i> , 2006, 240, 31-36.	0.6	67
8	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 460-468.	3.9	66
9	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , 2020, 35, 774-780.	3.9	57
10	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	3.9	47
11	Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome. <i>Journal of Neural Transmission</i> , 2005, 112, 1345-1353.	2.8	35
12	Genome-wide assessment of Parkinson's disease in a Southern Spanish population. <i>Neurobiology of Aging</i> , 2016, 45, 213.e3-213.e9.	3.1	35
13	Oxidative stress and plasma aminopeptidase activity in Huntington's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 325-332.	2.8	29
14	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 35-42.	5.3	29
15	Neurophysiological study in cerebrotendinous xanthomatosis. <i>Muscle and Nerve</i> , 2011, 43, 531-536.	2.2	25
16	Analysis of the genetic variability in Parkinson's disease from Southern Spain. <i>Neurobiology of Aging</i> , 2016, 37, 210.e1-210.e5.	3.1	23
17	Clinical and genetic characteristics of late-onset Huntington's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 101-105.	2.2	17
18	Functional rehabilitation of upper limb apraxia in poststroke patients: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 508.	1.6	14

#	ARTICLE	IF	CITATIONS
19	Oxidative Stress and Aminopeptidases in Parkinson's Disease Patients with and without Treatment. <i>Neurodegenerative Diseases</i> , 2011, 8, 109-116.	1.4	12
20	Structural genomic variations and Parkinson's disease. <i>Minerva Medica</i> , 2017, 108, 438-447.	0.9	11
21	Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN. <i>Revista Clínica Española</i> , 2018, 218, 327-335.	0.6	10
22	Utility of transcranial sonography in the diagnosis of drug-induced parkinsonism: a prospective study. <i>European Journal of Neurology</i> , 2013, 20, 1451-1458.	3.3	9
23	Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. <i>PLoS ONE</i> , 2020, 15, e0230846.	2.5	9
24	Long-term effectiveness of glatiramer acetate in clinical practice conditions. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2212-2218.	1.5	8
25	Effectiveness of a Functional Rehabilitation Program for Upper Limb Apraxia in Poststroke Patients: A Randomized Controlled Trial. <i>Archives of Physical Medicine and Rehabilitation</i> , 2021, 102, 940-950.	0.9	8
26	Plasma Aminopeptidase Activities in Parkinson's Disease. <i>Hormone and Metabolic Research</i> , 2006, 38, 758-760.	1.5	7
27	Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis. <i>Molecular Neurobiology</i> , 2021, 58, 4716-4726.	4.0	4
28	Angiografía por tomografía de coherencia óptica en el diagnóstico precoz del síndrome de Susac. <i>Neurología</i> , 2020, 35, 62-63.	0.7	3
29	Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod. <i>Case Reports in Neurology</i> , 2022, 14, 38-43.	0.7	3
30	Neurorretinitis y trombosis venosa intracraneal en el síndrome antifosfolípido. <i>Neurología</i> , 2014, 29, 318-320.	0.7	2
31	Smoking is associated with age at disease onset in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 79-83.	2.2	2
32	Corea generalizada de etiología paraneoplásica asociada a anticuerpos antiSOX-1. <i>Neurología Argentina</i> , 2021, 13, 55-57.	0.3	0
33	When a stroke is not a stroke. <i>Emergencias</i> , 2018, 30, 136-137.	0.6	0